LONDON December 12th, 2021- Immunidex Ltd, an innovative AI healthcare startup, has analysed data from thousands of hospitalized patients infected with the COVID-19, using blood-based biomarkers. In particular, Immunidex is working on applications to assess patients’ immune risk of severe COVID-19 infection. Its unique approach identifies blood-based biomarkers which can indicate high susceptibility to disease, such as carbohydrates/lipids management and kidney/liver function.
During the first wave of the COVID-19 pandemic in 2019, much was unknown about the novel coronavirus. Scientists were, nonetheless, aware that older people were at higher risk of severe COVID-19 infection and mortality [1]. With time, research has suggested other influences and risk factors beyond advanced age. Immunidex’s pre-findings reveal that obesity, diabetes hypertension, as well as impaired liver and kidney functions, significantly increase the need for patient hospitalization. Importantly, it has also been observed that hospitalized COVID-19 patients are frequently Vitamin D deficient. These clinical findings correlate to scientific outcomes where increased levels of Vitamin D supplementation have decreased the severity of COVID-19 infection and the number of virus-affected lung segments in COVID-19-positive patients [2]. Immunidex is excited that its applications to assess COVID-19 risk factors can provide an invaluable link between the latest scientific findings and effective clinical treatment during an ongoing pandemic.
1. Mueller, Amber L et al. “Why does COVID-19 disproportionately affect older people?.” Aging vol. 12,10 (2020): 9959-9981. doi:10.18632/aging.103344
2. Demir, Mustafa et al. “Vitamin D deficiency is associated with COVID-19 positivity and severity of the disease.” Journal of medical virology vol. 93,5 (2021): 2992-2999. doi:10.1002/jmv.26832
